NOTICE OF EXTRAORDINARY GENERAL MEETING IN SCN

(NGM: SCN)

The Board of Scandinavian Clinical Nutrition AB (SCN) today decided to propose an Extraordinary General Meeting to apply for de-listing of the company’s shares from Oslo Axess.

The Board proposes that the EGM decides to apply to Oslo Börs for de-listing of the Company’s shares from Oslo Axess. No change is however proposed regarding the listing on NGM Equity. The Board’s motives for the proposal are in short the following:

• the trade in the Company’s shares on Oslo Axess has been very limited

• the spread of the shares in Norway is very limited

• a double stock exchange listing requires significant resources, both in terms of costs and workload

• the Company has its domicile and headquarters in Stockholm and its home state in Sweden

• the majority of the shareholders and other interested parties in the Company are Swedish

• the main part of the trade in the share takes place on Oslo Axess

• since the listing on NGM is proposed to remain, the interests of minority shareholders will still be accommodated

With the above in mind, the Board cannot defend that a company of SCN’s size carries the costs for a double stock exchange listing, and therefore proposes that the EGM authorizes the Board to apply for de-listing of the Company’s shares from Oslo Axess, and to take the measures necessary to carry this out.

The notice in full to the Extraordinary General Meeting can be found in the attached pdf file, which also is available on the company’s website www.scnutrition.com. The pdf file also contains an attendance form and a proxy form.

The notice will also be published in Dagens Industri, PoIT and Finansavisen on May 4, 2009.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, jea@scnutrition.com, +47 924 99 360

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.com.